Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117134027 | 11713402 | 7 | F | 201510 | 20160727 | 20151109 | 20160808 | EXP | CA-JNJFOC-20151024045 | JOHNSON AND JOHNSON | 61.00 | YR | A | F | Y | 0.00000 | 20160808 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117134027 | 11713402 | 1 | SS | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Unknown | 4 X | N | U | UNKNOWN | 0 | 500 | MG | UNSPECIFIED | ||||
| 117134027 | 11713402 | 2 | SS | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Unknown | X 8 | N | U | UNKNOWN | 0 | 500 | MG | UNSPECIFIED | ||||
| 117134027 | 11713402 | 3 | SS | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Unknown | N | U | UNKNOWN | 0 | UNSPECIFIED | |||||||
| 117134027 | 11713402 | 4 | SS | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Unknown | 4 X | N | U | UNKNOWN | 0 | 500 | MG | UNSPECIFIED | ||||
| 117134027 | 11713402 | 5 | PS | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Unknown | X 8 | N | U | UNKNOWN | 19872 | 500 | MG | UNSPECIFIED | ||||
| 117134027 | 11713402 | 6 | SS | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Unknown | N | U | UNKNOWN | 19872 | UNSPECIFIED | |||||||
| 117134027 | 11713402 | 7 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | N | 0 | TABLET | |||||||||
| 117134027 | 11713402 | 8 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | N | 0 | 5 | MG | TABLET | BID | ||||||
| 117134027 | 11713402 | 9 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | N | 0 | 5 | MG | TABLET | BID | ||||||
| 117134027 | 11713402 | 10 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | N | 0 | 5 | MG | TABLET | BID | ||||||
| 117134027 | 11713402 | 11 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | N | 0 | TABLET | |||||||||
| 117134027 | 11713402 | 12 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | N | 0 | 20 | MG | TABLET | |||||||
| 117134027 | 11713402 | 13 | SS | CELEBREX | CELECOXIB | 1 | Oral | N | 0 | 200 | MG | CAPSULE, HARD | BID | ||||||
| 117134027 | 11713402 | 14 | SS | CELEBREX | CELECOXIB | 1 | Oral | TO 200MG DIE (DAILY) FROM 200MG BID | N | 0 | 200 | MG | CAPSULE, HARD | ||||||
| 117134027 | 11713402 | 15 | SS | LYRICA | PREGABALIN | 1 | Oral | 0 | CAPSULE, HARD | ||||||||||
| 117134027 | 11713402 | 16 | SS | CORTISONE | CORTISONEHYDROCORTISONE | 1 | Unknown | 0 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 117134027 | 11713402 | 1 | Pain |
| 117134027 | 11713402 | 2 | Pain |
| 117134027 | 11713402 | 3 | Pain |
| 117134027 | 11713402 | 4 | Rheumatoid arthritis |
| 117134027 | 11713402 | 5 | Rheumatoid arthritis |
| 117134027 | 11713402 | 6 | Rheumatoid arthritis |
| 117134027 | 11713402 | 7 | Rheumatoid arthritis |
| 117134027 | 11713402 | 8 | Rheumatoid arthritis |
| 117134027 | 11713402 | 9 | Rheumatoid arthritis |
| 117134027 | 11713402 | 10 | Rheumatoid arthritis |
| 117134027 | 11713402 | 11 | Rheumatoid arthritis |
| 117134027 | 11713402 | 12 | Rheumatoid arthritis |
| 117134027 | 11713402 | 13 | Rheumatoid arthritis |
| 117134027 | 11713402 | 14 | Rheumatoid arthritis |
| 117134027 | 11713402 | 15 | Product used for unknown indication |
| 117134027 | 11713402 | 16 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 117134027 | 11713402 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 117134027 | 11713402 | Alopecia | |
| 117134027 | 11713402 | Bladder cancer | |
| 117134027 | 11713402 | Haemorrhage urinary tract | |
| 117134027 | 11713402 | Hepatic enzyme increased | |
| 117134027 | 11713402 | Middle insomnia | |
| 117134027 | 11713402 | Pain | |
| 117134027 | 11713402 | Poor quality sleep | |
| 117134027 | 11713402 | Urinary incontinence | |
| 117134027 | 11713402 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 117134027 | 11713402 | 8 | 20151019 | 20160104 | 0 | |
| 117134027 | 11713402 | 9 | 20150825 | 20151004 | 0 | |
| 117134027 | 11713402 | 10 | 20150806 | 20150811 | 0 | |
| 117134027 | 11713402 | 12 | 201504 | 201508 | 0 |